Alerts will be sent to your verified email
Verify EmailRPGLIFE
|
RPG Life Sciences
|
Advanced Enzyme Tech
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
-11.18 % | n/a | n/a |
|
R&D as a % of Total Sales
|
1.11 % | 10.41 % | 1.28 % |
|
Financials
|
|||
|
5 yr Average ROE
|
23.71 % | 10.77 % | 16.89 % |
|
5yr average Equity Multiplier
|
1.34 | 1.15 | 2.16 |
|
5yr Average Asset Turnover Ratio
|
1.18 | 0.41 | 0.75 |
|
5yr Avg Net Profit Margin
|
15.65 % | 22.63 % | 10.24 % |
|
Price to Book
|
6.21 | 2.39 | 5.43 |
|
P/E
|
32.65 | 23.13 | 56.24 |
|
5yr Avg Cash Conversion Cycle
|
-53.67 Days | 109.31 Days | -15.25 Days |
|
Inventory Days
|
61.98 Days | 77.49 Days | 71.73 Days |
|
Days Receivable
|
35.4 Days | 61.31 Days | 106.89 Days |
|
Days Payable
|
143.49 Days | 49.86 Days | 179.29 Days |
|
5yr Average Interest Coverage Ratio
|
30.59 | 54.21 | 8.9 |
|
5yr Avg ROCE
|
28.37 % | 14.52 % | 17.89 % |
|
5yr Avg Operating Profit Margin
|
20.94 % | 35.47 % | 18.12 % |
|
5 yr average Debt to Equity
|
0.0 | 0.02 | 0.67 |
|
5yr CAGR Net Profit
|
35.58 % | -2.12 % | -2.66 % |
|
5yr Average Return on Assets
|
17.85 % | 9.32 % | 7.7 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
72.95 % | 43.26 % | 72.5 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.14 % | -6.61 % | -2.5 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.04 % | -3.36 % | 2.6 % |
|
RPG Life Sciences
|
Advanced Enzyme Tech
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|